Effect of the thiazolidinedione antihyperglycaemic agent BRL 49653 on liver fatty acid binding protein gene expression.
Sidaway
J E
JE
School of Biological Sciences, University of Manchester, U.K.
Dickson
A J
AJ
Smith
S A
SA
Boam
D S
DS
D000818:Animals; D002352:Carrier Proteins / Q000096:biosynthesis*; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D018996:Myelin P2 Protein / Q000096:biosynthesis*; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D015345:Oligonucleotide Probes; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D011924:Rats, Zucker; D000077154:Rosiglitazone; D013844:Thiazoles / Q000494:pharmacology*; D045162:Thiazolidinediones; D014158:Transcription, Genetic / Q000187:drug effects*
D002352:Carrier Proteins; C490174:Fabp7 protein, rat; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D007004:Hypoglycemic Agents; D018996:Myelin P2 Protein; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D015345:Oligonucleotide Probes; D012333:RNA, Messenger; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone